These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 11493441)

  • 21. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.
    Stevens SJ; Verschuuren EA; Pronk I; van Der Bij W; Harmsen MC; The TH; Meijer CJ; van Den Brule AJ; Middeldorp JM
    Blood; 2001 Mar; 97(5):1165-71. PubMed ID: 11222357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
    Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
    Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
    [No Abstract]   [Full Text] [Related]  

  • 25. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome.
    Gross TG; Steinbuch M; DeFor T; Shapiro RS; McGlave P; Ramsay NK; Wagner JE; Filipovich AH
    Bone Marrow Transplant; 1999 Feb; 23(3):251-8. PubMed ID: 10084256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
    Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
    J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.
    Tsushima T; Masuda SI; Yoda N; Kainuma S; Kimeda C; Konno S; Tanaka K; Matsuo K; Shimoji S; Kimura K; Arai H; Utsu Y; Imadome KI; Aotsuka N
    Ann Hematol; 2024 Mar; 103(3):935-946. PubMed ID: 38157001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.
    Chiusolo P; Metafuni E; Cattani P; Piccirillo N; Santangelo R; Manzara S; Bellesi S; De Michele T; Leone G; Sica S
    J Clin Immunol; 2010 Nov; 30(6):894-902. PubMed ID: 20737201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients.
    Juvonen E; Aalto S; Tarkkanen J; Volin L; Hedman K; Ruutu T
    Haematologica; 2007 Jun; 92(6):819-25. PubMed ID: 17550855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
    Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
    Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
    Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation.
    Cohen JM; Sebire NJ; Harvey J; Gaspar HB; Cathy C; Jones A; Rao K; Cubitt D; Amrolia PJ; Davies EG; Veys P
    Blood; 2007 Sep; 110(6):2209-14. PubMed ID: 17502458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.
    Burns DM; Tierney R; Shannon-Lowe C; Croudace J; Inman C; Abbotts B; Nagra S; Fox CP; Chaganti S; Craddock CF; Moss P; Rickinson AB; Rowe M; Bell AI
    Blood; 2015 Dec; 126(25):2665-75. PubMed ID: 26450987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
    Dumas PY; Ruggeri A; Robin M; Crotta A; Abraham J; Forcade E; Bay JO; Michallet M; Bertrand Y; Socié G; Ionescu I; Gluckman E; Milpied N; Rocha V
    Bone Marrow Transplant; 2013 Feb; 48(2):253-6. PubMed ID: 22773124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
    Papalexandri A; Gavriilaki E; Vardi A; Kotsiou N; Demosthenous C; Constantinou N; Touloumenidou T; Zerva P; Kika F; Iskas M; Batsis I; Mallouri D; Yannaki E; Anagnostopoulos A; Sakellari I
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.